[go: up one dir, main page]

AU2004271807A1 - Oligonucleotides targeting prion diseases - Google Patents

Oligonucleotides targeting prion diseases Download PDF

Info

Publication number
AU2004271807A1
AU2004271807A1 AU2004271807A AU2004271807A AU2004271807A1 AU 2004271807 A1 AU2004271807 A1 AU 2004271807A1 AU 2004271807 A AU2004271807 A AU 2004271807A AU 2004271807 A AU2004271807 A AU 2004271807A AU 2004271807 A1 AU2004271807 A1 AU 2004271807A1
Authority
AU
Australia
Prior art keywords
oligonucleotide
prion
oligonucleotides
nucleotides
length
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004271807A
Other languages
English (en)
Inventor
Jean-Marc Juteau
Andrew Vaillant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Replicor Inc
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2003/004573 external-priority patent/WO2004024919A1/fr
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of AU2004271807A1 publication Critical patent/AU2004271807A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004271807A 2003-09-11 2004-09-10 Oligonucleotides targeting prion diseases Abandoned AU2004271807A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPCT/IB2003/004573 2003-09-11
PCT/IB2003/004573 WO2004024919A1 (fr) 2002-09-13 2003-09-11 Oligonucleotides antiviraux non complementaires de sequence
US58462704P 2004-06-06 2004-06-06
US60/584,627 2004-06-30
PCT/IB2004/003740 WO2005025487A2 (fr) 2003-09-11 2004-09-10 Oligonucleotides ciblant les maladies a prions

Publications (1)

Publication Number Publication Date
AU2004271807A1 true AU2004271807A1 (en) 2005-03-24

Family

ID=34315467

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004271807A Abandoned AU2004271807A1 (en) 2003-09-11 2004-09-10 Oligonucleotides targeting prion diseases

Country Status (4)

Country Link
EP (1) EP1667695A4 (fr)
AU (1) AU2004271807A1 (fr)
CA (1) CA2538245A1 (fr)
WO (1) WO2005025487A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119643A1 (fr) * 2005-05-12 2006-11-16 Replicor Inc. Molecules contre l'angiogenese oculaire et leurs utilisations
WO2006122409A1 (fr) * 2005-05-16 2006-11-23 Replicor Inc. Molecules antimicrobiennnes et leur utilisation
WO2006130949A1 (fr) * 2005-06-08 2006-12-14 Replicor Inc. Molecules contre des maladies liees a l'amyloide et leur utilisation
WO2007036016A1 (fr) * 2005-09-29 2007-04-05 Replicor Inc. Molécules thérapeutiques et leurs utilisations
JP2009511023A (ja) * 2005-10-06 2009-03-19 ユニバーシティー、オブ、デラウェア ハンチントン病の治療のためのｇに富むポリヌクレオチド
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2171231T3 (es) * 1995-10-26 2002-09-01 Winnacker Ernst Ludwig Prof Moleculas de acido nucleico capaces de distinguir prpc y prpsc de las proteinas prionicas y los procesos para su produccion.
GB0012054D0 (en) * 2000-05-18 2000-07-12 Isis Innovation Ligands
EP1333090A1 (fr) * 2002-02-01 2003-08-06 NascaCell GmbH Aptameres specifiques pour proteines de prion
AU2003267785C1 (en) * 2002-09-13 2009-12-24 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides

Also Published As

Publication number Publication date
WO2005025487A3 (fr) 2005-12-01
EP1667695A4 (fr) 2007-01-31
WO2005025487A2 (fr) 2005-03-24
EP1667695A2 (fr) 2006-06-14
WO2005025487A9 (fr) 2006-06-22
CA2538245A1 (fr) 2005-03-24

Similar Documents

Publication Publication Date Title
JP5514179B2 (ja) 非配列相補性の抗ウイルス性オリゴヌクレオチド
US9688987B2 (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
CN108064154B (zh) 用于抑制hao1(羟酸氧化酶1(乙醇酸盐氧化酶))基因表达的组合物及方法
TW202140509A (zh) 人類染色體９開讀框７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ劑組成物及其使用方法
US20070123480A1 (en) Oligonucleotides targeting prion diseases
JP2023523993A (ja) アポリポタンパク質Ｅ（ＡｐｏＥ）ｉＲＮＡ剤組成物およびその使用方法
TW202328453A (zh) 治療或預防以擴大的胞內體為特徵之疾病的ＡＰＰ ｉＲＮＡ組成物及其使用方法
US20100172965A1 (en) Antiviral oligonucleotides targeting viral families
AU2004271807A1 (en) Oligonucleotides targeting prion diseases
WO2006130949A1 (fr) Molecules contre des maladies liees a l'amyloide et leur utilisation
WO2006119643A1 (fr) Molecules contre l'angiogenese oculaire et leurs utilisations
WO2012005339A1 (fr) Agent de traitement prophylactique ou thérapeutique du diabète
US20090215873A1 (en) Therapeutic Molecules and their Uses
JP2025513757A (ja) ＳＮＣＡ関連疾患を処置するためのＳＮＣＡ標的化ｓｉＲＮＡ組成物

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application